The following information is disclosed in accordance with Rule 26 of the AIM Rules (July 2016). These requirements were last reviewed and updated by the company on 4th January 2021.

Description of BusinessRedx Pharma was formed in 2010 and is an established drug discovery and development company based at Alderley Park. The Group’s work has been endorsed by partnerships with global pharmaceutical companies, and focuses on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need in cancer and fibrosis.
Incorporation & Registered OfficeRedx Pharma Plc is registered in England & Wales number 07368089,
Block 33, Mereside, Alderley Park, Alderley Edge, Macclesfield SK10 4TG
DirectorsIain Ross (Chairman)
Lisa Anson (CEO)
Peter Presland (Non-Executive Director, Chairman of Audit & Disclosure Committee)
Dr Bernard Kirschbaum (Non-Executive Director)
Sarah Gordon Wild (Non-Executive Director)
Dr Thomas Burt (Non-Executive Director)
View Directors’ biographies
AdvisorsNominated Advisor
SPARK Advisory Partners Limited
5 St. John’s Lane,
London, EC1M 4BH, UK

WG Partners LLP
85 Gresham Street
London EC2V 7NQ, UK

3 Hardman Street
Manchester M3 3HF, UK

Financial Communications Advisor
FTI Consulting
200 Aldersgate Street
London EC1A 4HD, UK
Legal Advisors
Covington and Burling LLP
265 Strand
London WC2R 1BH, UK

Equiniti Limited
Aspect House
Spencer Road
West Sussex BN99 6DA, UK
Corporate GovernanceThe Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework. The main features of the Group’s corporate governance arrangements are:

  • The Board of Directors intends to meet 10 times per year for formal Board Meetings. It approves financial statements, dividends and significant changes in accounting practices and key commercial matters, such as decisions to be taken on whether to take forward or to cancel a scientific project. There is a formal schedule of matters reserved for decision by the Board in place.

  • The membership of the different committees is as to the right.

  • Changes to these committees were implemented after the arrival of the new Chairman on 1 May 2017.
Audit, Risk and Disclosure Committee
Peter Presland (C), Bernhard Kirschbaum and Sarah Gordon Wild

Committee terms of reference PDF

Remuneration Committee
Bernhard Kirschbaum (C), Peter Presland and Sarah Gordon Wild

Committee terms of reference PDF
Constitutional DocumentsArticles of Association PDF
Exchanges & Trading PlatformsThe Company is not listed on any other Exchanges or Trading Platforms.
Shares & Significant ShareholdersTotal number of shares issued: 273,887,213
Number of shares (if any) held in treasury: Nil

Shareholders with >3% of total issued:
NameNumber of sharesPercentage of issued shares
RM Special Holdings 3 LLP217,880,61079.55%
Sofinnova Crossover 1 SLP25,779,7519.41%
Polar Capital13,571,4294.96%
Last updated 04/01/2021
Shares Not in Public HandsPursuant to the AIM Rules, and insofar as the Company is aware, as at 04/01/2021, 89.48% of the Company’s AIM securities were not in public hands.
Share RestrictionsThere are no restrictions on the transfer of securities.
Admission DocumentCompany admission document PDF
Shareholder CircularsClick to view Shareholder Circulars
Takeover CodeThe Company is subject to the UK City Code on Takeovers and Mergers.
Latest Annual ReportClick to view the latest annual report
RNS AnnouncementsClick to view the company’s RNS Announcements